Mushroom-Derived compound joins forces with radiation and immunotherapy to fight advanced cancers

NCT ID NCT07267234

Not yet recruiting Disease control Sponsor: Second Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immune function and slows tumor growth. All participants receive the same treatment; there is no placebo group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRaG-1 Cordycepin Tablets (a natural compound from Cordyceps fungus) combined with radiation therapy, GM-CSF injections, and PD-1/PD-L1 inhibitors
What this could lead to: If this works, it could offer a new treatment option for people with advanced solid tumors who have run out of standard options.
What could go wrong: This is a small, early-phase trial with only 65 participants and no comparison group, so results may not apply broadly. The combination therapy may cause side effects or fail to slow tumor growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer lymphopenia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE CHECKPOINT INHIBITOR LYMPHOPENIA RADIOTHERAPY SOLID CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.